Testing by our group using multiplex assays identified elevated antibody titers against specific EBNA1 peptides and ANO2—but not CRYAB or GlialCAM—in MS patients compared to healthy controls; however, the number of MS patients tested was limited [87]. This evidence concerns the gene HEPACAM and myeloid sarcoma.